CRISPR Cas9-guided chromatin immunoprecipitation identifies miR483 as an epigenetic modulator of IGF2 imprinting in tumors
Metrics: PDF 1623 views | HTML 2303 views | ?
Yiqun Zhang1,2, Ji-Fan Hu1,2,*, Hong Wang1,2, Jiuwei Cui1, Sujun Gao1, Andrew R. Hoffman2,* and Wei Li1,*
1Stem Cell and Cancer Center, First Affiliated Hospital, Jilin University, Changchun, Jilin 130061, P.R. China
2Department of Medicine, Stanford University Medical School, VA Palo Alto Health Care System, Palo Alto, CA 94304, USA
*These authors are co-corresponding and senior authors of this report
Ji-Fan Hu, email: firstname.lastname@example.org
Wei Li, email: email@example.com
Andrew R. Hoffman, email: firstname.lastname@example.org.
Keywords: IGF2 imprinting, tumor, epigenetics, histone K27 methylation, allelic expression
Received: January 08, 2016 Accepted: July 18, 2016 Published: July 29, 2016
The normally imprinted insulin-like growth factor II (IGF2) gene is aberrantly upregulated in a variety of human malignancies, yet the mechanisms underlying this dysregulation are still poorly defined. In this report, we used a CRISPR Cas9-guided chromatin immunoprecipitation assay to characterize the molecular components that participate in the control of IGF2 gene expression in human tumor cells. We found that miR483, an oncogenic intronic miRNA, binds to the most upstream imprinted IGF2 promoter, P2. Ectopic expression of miR483 induced upregulation of IGF2 expression, in parallel with an increase in tumor cell proliferation, migration, invasion, and tumor colony formation. miR483 induced loss of IGF2 imprinting by altering the epigenotype at P2, with reduction in histone H3K27 methylation and a decrease in chromatin binding of two imprinting regulatory factors, CTCF and SUZ12. This study identifies a new role for miR483 in the regulation of IGF2 gene expression through the alteration of the promoter epigenotype.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.